Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mSAR'877
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
mSAR'877 is a murine surrogate of SAR445877, a novel antibody-cytokine fusion protein developed by Sanofi. It consists of a murine anti-PD-1 antibody fused to a mutated murine interleukin-15 (IL-15) and IL-15 receptor alpha sushi domain. The molecule is designed to cis-activate effector T cells by biasing IL-15 stimulation specifically to T cells expressing PD-1, thereby enhancing anti-tumor activity while potentially reducing systemic toxicities associated with untargeted IL-15. In preclinical B16-OVA mouse models, mSAR'877 has demonstrated superior efficacy compared to anti-PD-1 monotherapy or untargeted IL-15, characterized by increased tumor immune cell infiltration (CD8+ T cells and NK cells) and tumor regression.
- Other names
- murine surrogate anti-mPD-1-mutmIL15
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)PDCD1 (Programmed cell death protein 1 receptor)IL15 (Interleukin 15)
Beyond the preview
Go deeper on mSAR'877.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mSAR'877.